A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC).

Stopped This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns

Conditions

• Advanced Hepatocellular Carcinoma

Interventions

• DRUG: Penpulimab injection
• DRUG: TQB2618 injection
• DRUG: Anlotinib Hydrochloride Capsules

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.